These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35086552)

  • 21. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
    Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
    Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.
    Kyei GB; Meng S; Ramani R; Niu A; Lagisetti C; Webb TR; Ratner L
    mBio; 2018 Nov; 9(6):. PubMed ID: 30401776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Galbanic Acid on Proliferation, Migration, and Apoptosis of Glioblastoma Cells Through the PI3K/Akt/MTOR Signaling Pathway.
    Shahcheraghi SH; Lotfi M; Soukhtanloo M; Ghayour Mobarhan M; Jaliani HZ; Sadeghnia HR; Ghorbani A
    Curr Mol Pharmacol; 2021; 14(1):79-87. PubMed ID: 32394847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
    Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
    J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ICAT inhibits glioblastoma cell proliferation by suppressing Wnt/β-catenin activity.
    Zhang K; Zhu S; Liu Y; Dong X; Shi Z; Zhang A; Liu C; Chen L; Wei J; Pu P; Zhang J; Jiang T; Han L; Kang C
    Cancer Lett; 2015 Feb; 357(1):404-411. PubMed ID: 25434796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pre-mRNA splicing and transcription factor Tat-SF1 is a functional partner of the spliceosome SF3b1 subunit via a U2AF homology motif interface.
    Loerch S; Leach JR; Horner SW; Maji D; Jenkins JL; Pulvino MJ; Kielkopf CL
    J Biol Chem; 2019 Feb; 294(8):2892-2902. PubMed ID: 30567737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells.
    Mughal AA; Grieg Z; Skjellegrind H; Fayzullin A; Lamkhannat M; Joel M; Ahmed MS; Murrell W; Vik-Mo EO; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Aug; 14():160. PubMed ID: 26292663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant SF3B1 promotes malignancy in PDAC.
    Simmler P; Ioannidi EI; Mengis T; Marquart KF; Asawa S; Van-Lehmann K; Kahles A; Thomas T; Schwerdel C; Aceto N; Rätsch G; Stoffel M; Schwank G
    Elife; 2023 Oct; 12():. PubMed ID: 37823551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
    Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
    Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer.
    Simmler P; Cortijo C; Koch LM; Galliker P; Angori S; Bolck HA; Mueller C; Vukolic A; Mirtschink P; Christinat Y; Davidson NR; Lehmann KV; Pellegrini G; Pauli C; Lenggenhager D; Guccini I; Ringel T; Hirt C; Marquart KF; Schaefer M; Rätsch G; Peter M; Moch H; Stoffel M; Schwank G
    Cell Rep; 2022 Aug; 40(8):111266. PubMed ID: 36001976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.
    Liu B; Liu Z; Chen S; Ki M; Erickson C; Reis-Filho JS; Durham BH; Chang Q; de Stanchina E; Sun Y; Rabadan R; Abdel-Wahab O; Chandarlapaty S
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33031100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
    Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
    J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.